ID   CATD_HUMAN              Reviewed;         412 AA.
AC   P07339; Q6IB57;
DT   01-APR-1988, integrated into UniProtKB/Swiss-Prot.
DT   01-APR-1988, sequence version 1.
DT   10-MAY-2017, entry version 203.
DE   RecName: Full=Cathepsin D;
DE            EC=3.4.23.5;
DE   Contains:
DE     RecName: Full=Cathepsin D light chain;
DE   Contains:
DE     RecName: Full=Cathepsin D heavy chain;
DE   Flags: Precursor;
GN   Name=CTSD; Synonyms=CPSD;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=3927292; DOI=10.1073/pnas.82.15.4910;
RA   Faust P.L., Kornfeld S., Chirgwin J.M.;
RT   "Cloning and sequence analysis of cDNA for human cathepsin D.";
RL   Proc. Natl. Acad. Sci. U.S.A. 82:4910-4914(1985).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=3588310; DOI=10.1093/nar/15.9.3773;
RA   Westley B.R., May F.E.B.;
RT   "Oestrogen regulates cathepsin D mRNA levels in oestrogen responsive
RT   human breast cancer cells.";
RL   Nucleic Acids Res. 15:3773-3786(1987).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=2069717; DOI=10.1089/dna.1991.10.423;
RA   Redecker B., Heckendorf B., Grosch H.W., Mersmann G., Hasilik A.;
RT   "Molecular organization of the human cathepsin D gene.";
RL   DNA Cell Biol. 10:423-431(1991).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RA   Ebert L., Schick M., Neubert P., Schatten R., Henze S., Korn B.;
RT   "Cloning of human full open reading frames in Gateway(TM) system entry
RT   vector (pDONR201).";
RL   Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor
RT   vector.";
RL   Submitted (OCT-2004) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Kidney;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-22.
RX   PubMed=8262386; DOI=10.1016/0378-1119(93)90107-E;
RA   May F.E., Smith D.J., Westley B.R.;
RT   "The human cathepsin D-encoding gene is transcribed from an estrogen-
RT   regulated and a constitutive start point.";
RL   Gene 134:277-282(1993).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-22.
RX   PubMed=7935485; DOI=10.1210/mend.8.6.7935485;
RA   Augereau P., Miralles F., Cavailles V., Gaudelet C., Parker M.,
RA   Rochefort H.;
RT   "Characterization of the proximal estrogen-responsive element of human
RT   cathepsin D gene.";
RL   Mol. Endocrinol. 8:693-703(1994).
RN   [9]
RP   PROTEIN SEQUENCE OF 170-180.
RC   TISSUE=Liver;
RA   Hochstrasser D.F., Frutiger S., Paquet N., Bairoch A., Ravier F.,
RA   Pasquali C., Sanchez J.-C., Tissot J.-D., Bjellqvist B., Vargas R.,
RA   Appel R.D., Hughes G.J.;
RL   Submitted (JUN-1992) to UniProtKB.
RN   [10]
RP   PROTEIN SEQUENCE OF 154-162 AND 169-180, SUBUNIT, AND TISSUE
RP   SPECIFICITY.
RX   PubMed=1426530; DOI=10.1016/0020-711X(92)90076-D;
RA   Kobayashi T., Honke K., Gasa S., Fujii T., Maguchi S., Miyazaki T.,
RA   Makita A.;
RT   "Proteolytic processing sites producing the mature form of human
RT   cathepsin D.";
RL   Int. J. Biochem. 24:1487-1491(1992).
RN   [11]
RP   SUBCELLULAR LOCATION [LARGE SCALE ANALYSIS].
RC   TISSUE=Melanoma;
RX   PubMed=12643545; DOI=10.1021/pr025562r;
RA   Basrur V., Yang F., Kushimoto T., Higashimoto Y., Yasumoto K.,
RA   Valencia J., Muller J., Vieira W.D., Watabe H., Shabanowitz J.,
RA   Hearing V.J., Hunt D.F., Appella E.;
RT   "Proteomic analysis of early melanosomes: identification of novel
RT   melanosomal proteins.";
RL   J. Proteome Res. 2:69-79(2003).
RN   [12]
RP   GLYCOSYLATION AT ASN-263.
RX   PubMed=12754519; DOI=10.1038/nbt827;
RA   Zhang H., Li X.-J., Martin D.B., Aebersold R.;
RT   "Identification and quantification of N-linked glycoproteins using
RT   hydrazide chemistry, stable isotope labeling and mass spectrometry.";
RL   Nat. Biotechnol. 21:660-666(2003).
RN   [13]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-263.
RC   TISSUE=Plasma;
RX   PubMed=16335952; DOI=10.1021/pr0502065;
RA   Liu T., Qian W.-J., Gritsenko M.A., Camp D.G. II, Monroe M.E.,
RA   Moore R.J., Smith R.D.;
RT   "Human plasma N-glycoproteome analysis by immunoaffinity subtraction,
RT   hydrazide chemistry, and mass spectrometry.";
RL   J. Proteome Res. 4:2070-2080(2005).
RN   [14]
RP   INVOLVEMENT IN CLN10, AND VARIANT ARG-282.
RX   PubMed=16670177; DOI=10.1093/brain/awl107;
RA   Siintola E., Partanen S., Stromme P., Haapanen A., Haltia M.,
RA   Maehlen J., Lehesjoki A.E., Tyynela J.;
RT   "Cathepsin D deficiency underlies congenital human neuronal ceroid-
RT   lipofuscinosis.";
RL   Brain 129:1438-1445(2006).
RN   [15]
RP   SUBCELLULAR LOCATION [LARGE SCALE ANALYSIS].
RC   TISSUE=Melanoma;
RX   PubMed=17081065; DOI=10.1021/pr060363j;
RA   Chi A., Valencia J.C., Hu Z.-Z., Watabe H., Yamaguchi H.,
RA   Mangini N.J., Huang H., Canfield V.A., Cheng K.C., Yang F., Abe R.,
RA   Yamagishi S., Shabanowitz J., Hearing V.J., Wu C., Appella E.,
RA   Hunt D.F.;
RT   "Proteomic and bioinformatic characterization of the biogenesis and
RT   function of melanosomes.";
RL   J. Proteome Res. 5:3135-3144(2006).
RN   [16]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-263.
RC   TISSUE=Platelet;
RX   PubMed=16263699; DOI=10.1074/mcp.M500324-MCP200;
RA   Lewandrowski U., Moebius J., Walter U., Sickmann A.;
RT   "Elucidation of N-glycosylation sites on human platelet proteins: a
RT   glycoproteomic approach.";
RL   Mol. Cell. Proteomics 5:226-233(2006).
RN   [17]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-134 AND ASN-263.
RC   TISSUE=Liver;
RX   PubMed=19159218; DOI=10.1021/pr8008012;
RA   Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.;
RT   "Glycoproteomics analysis of human liver tissue by combination of
RT   multiple enzyme digestion and hydrazide chemistry.";
RL   J. Proteome Res. 8:651-661(2009).
RN   [18]
RP   TISSUE SPECIFICITY, AND SUBCELLULAR LOCATION.
RX   PubMed=20551380; DOI=10.1074/mcp.M110.001693;
RA   Didangelos A., Yin X., Mandal K., Baumert M., Jahangiri M., Mayr M.;
RT   "Proteomics characterization of extracellular space components in the
RT   human aorta.";
RL   Mol. Cell. Proteomics 9:2048-2062(2010).
RN   [19]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [20]
RP   GLYCOSYLATION AT THR-63, AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=23234360; DOI=10.1021/pr300963h;
RA   Halim A., Ruetschi U., Larson G., Nilsson J.;
RT   "LC-MS/MS characterization of O-glycosylation sites and glycan
RT   structures of human cerebrospinal fluid glycoproteins.";
RL   J. Proteome Res. 12:573-584(2013).
RN   [21]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [22]
RP   CLEAVAGE OF PROPEPTIDE [LARGE SCALE ANALYSIS] AFTER GLU-64, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M.,
RA   Ayoub D., Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [23]
RP   INTERACTION WITH ADAM30, IDENTIFICATION BY MASS SPECTROMETRY, AND
RP   CLEAVAGE.
RX   PubMed=27333034; DOI=10.1016/j.ebiom.2016.06.002;
RA   Letronne F., Laumet G., Ayral A.M., Chapuis J., Demiautte F., Laga M.,
RA   Vandenberghe M.E., Malmanche N., Leroux F., Eysert F., Sottejeau Y.,
RA   Chami L., Flaig A., Bauer C., Dourlen P., Lesaffre M., Delay C.,
RA   Huot L., Dumont J., Werkmeister E., Lafont F., Mendes T.,
RA   Hansmannel F., Dermaut B., Deprez B., Herard A.S., Dhenain M.,
RA   Souedet N., Pasquier F., Tulasne D., Berr C., Hauw J.J., Lemoine Y.,
RA   Amouyel P., Mann D., Deprez R., Checler F., Hot D., Delzescaux T.,
RA   Gevaert K., Lambert J.C.;
RT   "ADAM30 Downregulates APP-Linked Defects Through Cathepsin D
RT   Activation in Alzheimer's Disease.";
RL   EBioMedicine 9:278-292(2016).
RN   [24]
RP   X-RAY CRYSTALLOGRAPHY (3 ANGSTROMS).
RC   TISSUE=Spleen;
RX   PubMed=8467789;
RA   Metcalf P., Fusek M.;
RT   "Two crystal structures for cathepsin D: the lysosomal targeting
RT   signal and active site.";
RL   EMBO J. 12:1293-1302(1993).
RN   [25]
RP   X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS), AND SUBUNIT.
RC   TISSUE=Liver;
RX   PubMed=8393577; DOI=10.1073/pnas.90.14.6796;
RA   Baldwin E.T., Bhat T.N., Gulnik S., Hosur M.V., Sowder R.C. II,
RA   Cachau R.E., Collins J., Silva A.M., Erickson J.W.;
RT   "Crystal structures of native and inhibited forms of human cathepsin
RT   D: implications for lysosomal targeting and drug design.";
RL   Proc. Natl. Acad. Sci. U.S.A. 90:6796-6800(1993).
RN   [26]
RP   VARIANT VAL-58.
RX   PubMed=10716266;
RX   DOI=10.1002/1531-8249(200003)47:3<399::AID-ANA22>3.3.CO;2-X;
RA   Papassotiropoulos A., Bagli M., Kurz A., Kornhuber J., Forstl H.,
RA   Maier W., Pauls J., Lautenschlager N., Heun R.;
RT   "A genetic variation of cathepsin D is a major risk factor for
RT   Alzheimer's disease.";
RL   Ann. Neurol. 47:399-403(2000).
RN   [27]
RP   VARIANTS CLN10 ILE-229 AND CYS-383.
RX   PubMed=16685649; DOI=10.1086/504159;
RA   Steinfeld R., Reinhardt K., Schreiber K., Hillebrand M., Kraetzner R.,
RA   Bruck W., Saftig P., Gartner J.;
RT   "Cathepsin D deficiency is associated with a human neurodegenerative
RT   disorder.";
RL   Am. J. Hum. Genet. 78:988-998(2006).
RN   [28]
RP   VARIANT CLN10 ILE-229.
RX   PubMed=21990111; DOI=10.1002/humu.21624;
RA   Kousi M., Lehesjoki A.E., Mole S.E.;
RT   "Update of the mutation spectrum and clinical correlations of over 360
RT   mutations in eight genes that underlie the neuronal ceroid
RT   lipofuscinoses.";
RL   Hum. Mutat. 33:42-63(2012).
CC   -!- FUNCTION: Acid protease active in intracellular protein breakdown.
CC       Plays a role in APP processing following cleavage and activation
CC       by ADAM30 which leads to APP degradation (PubMed:27333034).
CC       Involved in the pathogenesis of several diseases such as breast
CC       cancer and possibly Alzheimer disease.
CC       {ECO:0000269|PubMed:27333034}.
CC   -!- CATALYTIC ACTIVITY: Specificity similar to, but narrower than,
CC       that of pepsin A. Does not cleave the 4-Gln-|-His-5 bond in B
CC       chain of insulin.
CC   -!- SUBUNIT: Consists of a light chain and a heavy chain
CC       (PubMed:8393577, PubMed:1426530). Interacts with ADAM30; this
CC       leads to activation of CTSD (PubMed:27333034).
CC       {ECO:0000269|PubMed:1426530, ECO:0000269|PubMed:27333034,
CC       ECO:0000269|PubMed:8393577}.
CC   -!- INTERACTION:
CC       P05067:APP; NbExp=2; IntAct=EBI-2115097, EBI-77613;
CC   -!- SUBCELLULAR LOCATION: Lysosome. Melanosome. Secreted,
CC       extracellular space. Note=Identified by mass spectrometry in
CC       melanosome fractions from stage I to stage IV. In aortic samples,
CC       detected as an extracellular protein loosely bound to the matrix
CC       (PubMed:20551380). {ECO:0000269|PubMed:20551380}.
CC   -!- TISSUE SPECIFICITY: Expressed in the aorta extrcellular space (at
CC       protein level) (PubMed:20551380). Expressed in liver (at protein
CC       level) (PubMed:1426530). {ECO:0000269|PubMed:1426530,
CC       ECO:0000269|PubMed:20551380}.
CC   -!- PTM: N- and O-glycosylated. {ECO:0000269|PubMed:12754519,
CC       ECO:0000269|PubMed:16263699, ECO:0000269|PubMed:16335952,
CC       ECO:0000269|PubMed:19159218, ECO:0000269|PubMed:23234360}.
CC   -!- PTM: Undergoes proteolytic cleavage and activation by ADAM30.
CC       {ECO:0000269|PubMed:27333034}.
CC   -!- PTM: As well as the major heavy chain which starts at Leu-169, 2
CC       minor forms starting at Gly-170 and Gly-171 have been identified
CC       (PubMed:1426530). An additional form starting at Ala-168 has also
CC       been identified (PubMed:27333034). {ECO:0000269|PubMed:1426530,
CC       ECO:0000269|PubMed:27333034}.
CC   -!- POLYMORPHISM: The Val-58 allele is significantly overrepresented
CC       in demented patients (11.8%) compared with non-demented controls
CC       (4.9%). Carriers of the Val-58 allele have a 3.1-fold increased
CC       risk for developing AD than non-carriers.
CC   -!- DISEASE: Ceroid lipofuscinosis, neuronal, 10 (CLN10) [MIM:610127]:
CC       A form of neuronal ceroid lipofuscinosis with onset at birth or
CC       early childhood. Neuronal ceroid lipofuscinoses are progressive
CC       neurodegenerative, lysosomal storage diseases characterized by
CC       intracellular accumulation of autofluorescent liposomal material,
CC       and clinically by seizures, dementia, visual loss, and/or cerebral
CC       atrophy. {ECO:0000269|PubMed:16670177,
CC       ECO:0000269|PubMed:16685649, ECO:0000269|PubMed:21990111}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- SIMILARITY: Belongs to the peptidase A1 family. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=NCL CTSD; Note=Neural Ceroid Lipofuscinoses
CC       mutation db;
CC       URL="http://www.ucl.ac.uk/ncl/catD.shtml";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M11233; AAB59529.1; -; mRNA.
DR   EMBL; X05344; CAA28955.1; -; mRNA.
DR   EMBL; M63138; AAA51922.1; -; Genomic_DNA.
DR   EMBL; M63134; AAA51922.1; JOINED; Genomic_DNA.
DR   EMBL; M63135; AAA51922.1; JOINED; Genomic_DNA.
DR   EMBL; M63136; AAA51922.1; JOINED; Genomic_DNA.
DR   EMBL; M63137; AAA51922.1; JOINED; Genomic_DNA.
DR   EMBL; CR456947; CAG33228.1; -; mRNA.
DR   EMBL; BT006910; AAP35556.1; -; mRNA.
DR   EMBL; BT020155; AAV38957.1; -; mRNA.
DR   EMBL; BC016320; AAH16320.1; -; mRNA.
DR   EMBL; L12980; AAA16314.1; -; Genomic_DNA.
DR   EMBL; S74689; AAD14156.1; -; Genomic_DNA.
DR   EMBL; S52557; AAD13868.1; -; Genomic_DNA.
DR   CCDS; CCDS7725.1; -.
DR   PIR; A25771; KHHUD.
DR   RefSeq; NP_001900.1; NM_001909.4.
DR   UniGene; Hs.654447; -.
DR   PDB; 1LYA; X-ray; 2.50 A; A/C=65-161, B/D=170-410.
DR   PDB; 1LYB; X-ray; 2.50 A; A/C=65-161, B/D=170-410.
DR   PDB; 1LYW; X-ray; 2.50 A; A/C/E/G=65-161, B/D/F/H=170-410.
DR   PDB; 4OBZ; X-ray; 2.90 A; A/C=60-162, B/D=170-412.
DR   PDB; 4OC6; X-ray; 2.64 A; A=60-162, B=170-412.
DR   PDB; 4OD9; X-ray; 1.90 A; A/C=60-162, B/D=170-412.
DR   PDBsum; 1LYA; -.
DR   PDBsum; 1LYB; -.
DR   PDBsum; 1LYW; -.
DR   PDBsum; 4OBZ; -.
DR   PDBsum; 4OC6; -.
DR   PDBsum; 4OD9; -.
DR   ProteinModelPortal; P07339; -.
DR   SMR; P07339; -.
DR   BioGrid; 107889; 45.
DR   DIP; DIP-43906N; -.
DR   IntAct; P07339; 21.
DR   MINT; MINT-3005628; -.
DR   STRING; 9606.ENSP00000236671; -.
DR   BindingDB; P07339; -.
DR   ChEMBL; CHEMBL2581; -.
DR   DrugBank; DB03028; 1h-Benoximidazole-2-Carboxylic Acid.
DR   DrugBank; DB07542; 5-AMINO-6-CYCLOHEXYL-4-HYDROXY-2-ISOBUTYL-HEXANOIC ACID.
DR   DrugBank; DB00030; Insulin Human.
DR   DrugBank; DB00071; Insulin Pork.
DR   DrugBank; DB03096; N-Aminoethylmorpholine.
DR   DrugBank; DB02216; S-Methylcysteine.
DR   GuidetoPHARMACOLOGY; 2345; -.
DR   MEROPS; A01.009; -.
DR   iPTMnet; P07339; -.
DR   PhosphoSitePlus; P07339; -.
DR   SwissPalm; P07339; -.
DR   BioMuta; CTSD; -.
DR   DMDM; 115717; -.
DR   DOSAC-COBS-2DPAGE; P07339; -.
DR   REPRODUCTION-2DPAGE; IPI00011229; -.
DR   SWISS-2DPAGE; P07339; -.
DR   UCD-2DPAGE; P07339; -.
DR   EPD; P07339; -.
DR   PaxDb; P07339; -.
DR   PeptideAtlas; P07339; -.
DR   PRIDE; P07339; -.
DR   TopDownProteomics; P07339; -.
DR   DNASU; 1509; -.
DR   Ensembl; ENST00000236671; ENSP00000236671; ENSG00000117984.
DR   GeneID; 1509; -.
DR   KEGG; hsa:1509; -.
DR   CTD; 1509; -.
DR   DisGeNET; 1509; -.
DR   GeneCards; CTSD; -.
DR   GeneReviews; CTSD; -.
DR   H-InvDB; HIX0009359; -.
DR   HGNC; HGNC:2529; CTSD.
DR   HPA; CAB000109; -.
DR   HPA; HPA003001; -.
DR   MalaCards; CTSD; -.
DR   MIM; 116840; gene.
DR   MIM; 610127; phenotype.
DR   neXtProt; NX_P07339; -.
DR   OpenTargets; ENSG00000117984; -.
DR   Orphanet; 228337; CLN10 disease.
DR   PharmGKB; PA27029; -.
DR   eggNOG; KOG1339; Eukaryota.
DR   eggNOG; ENOG410XNV7; LUCA.
DR   GeneTree; ENSGT00760000118929; -.
DR   HOGENOM; HOG000197681; -.
DR   HOVERGEN; HBG000482; -.
DR   InParanoid; P07339; -.
DR   KO; K01379; -.
DR   OMA; KVERQVF; -.
DR   OrthoDB; EOG091G0JP7; -.
DR   PhylomeDB; P07339; -.
DR   TreeFam; TF314990; -.
DR   BioCyc; MetaCyc:HS04183-MONOMER; -.
DR   BRENDA; 3.4.23.5; 2681.
DR   Reactome; R-HSA-1442490; Collagen degradation.
DR   Reactome; R-HSA-2022377; Metabolism of Angiotensinogen to Angiotensins.
DR   Reactome; R-HSA-2132295; MHC class II antigen presentation.
DR   Reactome; R-HSA-6798695; Neutrophil degranulation.
DR   EvolutionaryTrace; P07339; -.
DR   GeneWiki; Cathepsin_D; -.
DR   GenomeRNAi; 1509; -.
DR   PMAP-CutDB; P07339; -.
DR   PRO; PR:P07339; -.
DR   Proteomes; UP000005640; Chromosome 11.
DR   Bgee; ENSG00000117984; -.
DR   CleanEx; HS_CTSD; -.
DR   ExpressionAtlas; P07339; baseline and differential.
DR   Genevisible; P07339; HS.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:0005615; C:extracellular space; IDA:UniProtKB.
DR   GO; GO:1904813; C:ficolin-1-rich granule lumen; TAS:Reactome.
DR   GO; GO:0043202; C:lysosomal lumen; TAS:Reactome.
DR   GO; GO:0005764; C:lysosome; IDA:UniProtKB.
DR   GO; GO:0042470; C:melanosome; IEA:UniProtKB-SubCell.
DR   GO; GO:0045121; C:membrane raft; IDA:UniProtKB.
DR   GO; GO:0035580; C:specific granule lumen; TAS:Reactome.
DR   GO; GO:1904724; C:tertiary granule lumen; TAS:Reactome.
DR   GO; GO:0004190; F:aspartic-type endopeptidase activity; IBA:GO_Central.
DR   GO; GO:0004197; F:cysteine-type endopeptidase activity; TAS:Reactome.
DR   GO; GO:0004252; F:serine-type endopeptidase activity; TAS:Reactome.
DR   GO; GO:0019886; P:antigen processing and presentation of exogenous peptide antigen via MHC class II; TAS:Reactome.
DR   GO; GO:0006914; P:autophagy; IBA:GO_Central.
DR   GO; GO:0030574; P:collagen catabolic process; TAS:Reactome.
DR   GO; GO:0043312; P:neutrophil degranulation; TAS:Reactome.
DR   GO; GO:0030163; P:protein catabolic process; IBA:GO_Central.
DR   GO; GO:0006508; P:proteolysis; IBA:GO_Central.
DR   CDD; cd05490; Cathepsin_D2; 1.
DR   Gene3D; 2.40.70.10; -; 2.
DR   InterPro; IPR001461; Aspartic_peptidase_A1.
DR   InterPro; IPR001969; Aspartic_peptidase_AS.
DR   InterPro; IPR012848; Aspartic_peptidase_N.
DR   InterPro; IPR033736; Cathepsin_chordata.
DR   InterPro; IPR033144; Cathepsin_D.
DR   InterPro; IPR033121; PEPTIDASE_A1.
DR   InterPro; IPR021109; Peptidase_aspartic_dom.
DR   PANTHER; PTHR13683; PTHR13683; 1.
DR   PANTHER; PTHR13683:SF487; PTHR13683:SF487; 1.
DR   Pfam; PF07966; A1_Propeptide; 1.
DR   Pfam; PF00026; Asp; 1.
DR   PRINTS; PR00792; PEPSIN.
DR   SUPFAM; SSF50630; SSF50630; 1.
DR   PROSITE; PS00141; ASP_PROTEASE; 2.
DR   PROSITE; PS51767; PEPTIDASE_A1; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alzheimer disease; Aspartyl protease; Complete proteome;
KW   Direct protein sequencing; Disease mutation; Disulfide bond;
KW   Glycoprotein; Hydrolase; Lysosome; Neurodegeneration;
KW   Neuronal ceroid lipofuscinosis; Polymorphism; Protease;
KW   Reference proteome; Secreted; Signal; Zymogen.
FT   SIGNAL        1     20       {ECO:0000255}.
FT   PROPEP       21     64       Activation peptide.
FT                                {ECO:0000244|PubMed:25944712}.
FT                                /FTId=PRO_0000025949.
FT   CHAIN        65    412       Cathepsin D.
FT                                /FTId=PRO_0000025950.
FT   CHAIN        65    162       Cathepsin D light chain.
FT                                {ECO:0000305|PubMed:1426530}.
FT                                /FTId=PRO_0000025951.
FT   CHAIN       169    412       Cathepsin D heavy chain.
FT                                {ECO:0000305|PubMed:1426530}.
FT                                /FTId=PRO_0000025952.
FT   DOMAIN       79    407       Peptidase A1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU01103}.
FT   ACT_SITE     97     97       {ECO:0000255|PROSITE-ProRule:PRU10094,
FT                                ECO:0000269|PubMed:8393577}.
FT   ACT_SITE    295    295       {ECO:0000255|PROSITE-ProRule:PRU10094,
FT                                ECO:0000269|PubMed:8393577}.
FT   CARBOHYD     63     63       O-linked (GalNAc...) threonine.
FT                                {ECO:0000269|PubMed:23234360}.
FT   CARBOHYD    134    134       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:19159218}.
FT   CARBOHYD    263    263       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:12754519,
FT                                ECO:0000269|PubMed:16263699,
FT                                ECO:0000269|PubMed:16335952,
FT                                ECO:0000269|PubMed:19159218,
FT                                ECO:0000269|PubMed:8393577}.
FT   DISULFID     91    160       {ECO:0000269|PubMed:8393577}.
FT   DISULFID    110    117       {ECO:0000269|PubMed:8393577}.
FT   DISULFID    286    290       {ECO:0000269|PubMed:8393577}.
FT   DISULFID    329    366
FT   VARIANT      58     58       A -> V (associated with increased risk
FT                                for AD; possibly influences secretion and
FT                                intracellular maturation; dbSNP:rs17571).
FT                                {ECO:0000269|PubMed:10716266}.
FT                                /FTId=VAR_011621.
FT   VARIANT     229    229       F -> I (in CLN10; dbSNP:rs121912789).
FT                                {ECO:0000269|PubMed:16685649,
FT                                ECO:0000269|PubMed:21990111}.
FT                                /FTId=VAR_029362.
FT   VARIANT     282    282       G -> R (in dbSNP:rs147278302).
FT                                {ECO:0000269|PubMed:16670177}.
FT                                /FTId=VAR_058490.
FT   VARIANT     383    383       W -> C (in CLN10; dbSNP:rs121912790).
FT                                {ECO:0000269|PubMed:16685649}.
FT                                /FTId=VAR_029363.
FT   STRAND       67     74       {ECO:0000244|PDB:4OD9}.
FT   TURN         75     77       {ECO:0000244|PDB:4OD9}.
FT   STRAND       78     85       {ECO:0000244|PDB:4OD9}.
FT   TURN         86     89       {ECO:0000244|PDB:4OD9}.
FT   STRAND       90     97       {ECO:0000244|PDB:4OD9}.
FT   STRAND      103    107       {ECO:0000244|PDB:4OD9}.
FT   HELIX       115    118       {ECO:0000244|PDB:4OD9}.
FT   HELIX       125    127       {ECO:0000244|PDB:4OD9}.
FT   STRAND      132    141       {ECO:0000244|PDB:4OD9}.
FT   STRAND      146    159       {ECO:0000244|PDB:4OD9}.
FT   STRAND      172    184       {ECO:0000244|PDB:4OD9}.
FT   HELIX       189    192       {ECO:0000244|PDB:4OD9}.
FT   STRAND      194    200       {ECO:0000244|PDB:4OD9}.
FT   HELIX       204    206       {ECO:0000244|PDB:4OD9}.
FT   HELIX       208    210       {ECO:0000244|PDB:4OD9}.
FT   HELIX       214    220       {ECO:0000244|PDB:4OD9}.
FT   STRAND      224    226       {ECO:0000244|PDB:4OD9}.
FT   STRAND      228    233       {ECO:0000244|PDB:4OD9}.
FT   STRAND      236    238       {ECO:0000244|PDB:1LYW}.
FT   STRAND      239    249       {ECO:0000244|PDB:4OD9}.
FT   HELIX       252    254       {ECO:0000244|PDB:4OD9}.
FT   STRAND      255    263       {ECO:0000244|PDB:4OD9}.
FT   TURN        267    270       {ECO:0000244|PDB:4OD9}.
FT   STRAND      271    274       {ECO:0000244|PDB:4OD9}.
FT   STRAND      276    279       {ECO:0000244|PDB:4OD9}.
FT   TURN        280    282       {ECO:0000244|PDB:1LYW}.
FT   STRAND      284    286       {ECO:0000244|PDB:4OD9}.
FT   STRAND      290    294       {ECO:0000244|PDB:4OD9}.
FT   STRAND      299    303       {ECO:0000244|PDB:4OD9}.
FT   HELIX       305    314       {ECO:0000244|PDB:4OD9}.
FT   STRAND      318    321       {ECO:0000244|PDB:1LYA}.
FT   STRAND      325    327       {ECO:0000244|PDB:4OD9}.
FT   HELIX       329    334       {ECO:0000244|PDB:4OD9}.
FT   STRAND      338    342       {ECO:0000244|PDB:4OD9}.
FT   STRAND      345    349       {ECO:0000244|PDB:4OD9}.
FT   HELIX       351    354       {ECO:0000244|PDB:4OD9}.
FT   STRAND      355    360       {ECO:0000244|PDB:4OD9}.
FT   STRAND      363    372       {ECO:0000244|PDB:4OD9}.
FT   TURN        377    379       {ECO:0000244|PDB:4OD9}.
FT   STRAND      383    385       {ECO:0000244|PDB:4OD9}.
FT   HELIX       387    392       {ECO:0000244|PDB:4OD9}.
FT   STRAND      393    398       {ECO:0000244|PDB:4OD9}.
FT   TURN        399    402       {ECO:0000244|PDB:4OD9}.
FT   STRAND      403    409       {ECO:0000244|PDB:4OD9}.
SQ   SEQUENCE   412 AA;  44552 MW;  903FB8412E0CF0B0 CRC64;
     MQPSSLLPLA LCLLAAPASA LVRIPLHKFT SIRRTMSEVG GSVEDLIAKG PVSKYSQAVP
     AVTEGPIPEV LKNYMDAQYY GEIGIGTPPQ CFTVVFDTGS SNLWVPSIHC KLLDIACWIH
     HKYNSDKSST YVKNGTSFDI HYGSGSLSGY LSQDTVSVPC QSASSASALG GVKVERQVFG
     EATKQPGITF IAAKFDGILG MAYPRISVNN VLPVFDNLMQ QKLVDQNIFS FYLSRDPDAQ
     PGGELMLGGT DSKYYKGSLS YLNVTRKAYW QVHLDQVEVA SGLTLCKEGC EAIVDTGTSL
     MVGPVDEVRE LQKAIGAVPL IQGEYMIPCE KVSTLPAITL KLGGKGYKLS PEDYTLKVSQ
     AGKTLCLSGF MGMDIPPPSG PLWILGDVFI GRYYTVFDRD NNRVGFAEAA RL
//
